Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.32 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22030756 | 0.80 | ALDH1A1 (0.41) | ALDH1A1HSD11B1L3MBTL1LIPEMEN1 | |
| SCHEMBL23126224 | 0.76 | ALDH1A1 (0.38) | ALDH1A1HSD11B1L3MBTL1LIPEMEN1 | |
| SCHEMBL20070428 | 0.76 | HRH3 (0.38) | ALDH1A1LIPECA2CHKA | |
| SCHEMBL16456476 | 0.76 | SMN1; SMN2 (0.37) | HSD11B1SMN1; SMN2 | |
| SCHEMBL25862843 | 0.74 | CYP1A2 (0.39) | ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL21158719 | 0.73 | ALDH1A1 (0.35) | ALDH1A1HSD11B1LIPECA2CHKA | |
| SCHEMBL19014181 | 0.72 | JAK2 (0.35) | HSD11B1CHRM1L3MBTL1SMN1; SMN2 | |
| SCHEMBL21159097 | 0.71 | CHRNB2 (0.39) | ALDH1A1HSD11B1CHRM1SMN1; SMN2 | |
| SCHEMBL11188411 | 0.71 | ALDH1A1 (0.61) | ALDH1A1HSD11B1MEN1KMT2ACA2 | |
| SCHEMBL24767229 | 0.70 | HSD11B1 (0.42) | ALDH1A1HSD11B1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | ALDH1A1 2868/4885HSD11B1 2343/4885CHRM1 2284/4885 |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | ALDH1A1 2868/4885HSD11B1 2343/4885CHRM1 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.